Zobrazeno 1 - 10
of 112
pro vyhledávání: '"63"'
Publikováno v:
Journal of Clinical Oncology. 6:1584-1589
Sixty-three patients with T-cell lymphoma (TCL) were analyzed to correlate morphological and immunological features with clinical presentation, response to therapy, and survival. Clinical presentation was severe, with 59% of patients having stage IV
Autor:
Quchang Ouyang, Shusen Wang, Shiying Yu, Zhongsheng Tong, Zefei Jiang, Wei Li, Jianjun Zou, Xichun Hu, Y Liu, Fei Ma, Xiaoyu Zhu, Huiping Li, Jifeng Feng, Binghe Xu
Publikováno v:
Journal of Clinical Oncology. 37:2610-2619
PURPOSE Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine,
Autor:
Nirav N. Shah, Donna Capozzi, Erica Casella, Lynn M. Schuchter, Jennifer S. Myers, Tara C. Gangadhar, Suzanne McGettigan
Publikováno v:
Journal of Oncology Practice. 12:e71-e76
Purpose: Over the last decade, the use of oral chemotherapy (OC) for the treatment of cancer has dramatically increased. Despite their route of administration, OCs pose many of the same risks as intravenous agents. In this quality improvement project
Autor:
Rebecca Elstrom, Ann S. LaCasce, Morton Coleman, Amy Chadburn, Julia Morrison, Peter Martin, John P. Leonard, Ken Cheung, Scott Ely, Julie M. Vose, Richard R. Furman, Jia Ruan, Shing M. Lee, Ethel Cesarman
Publikováno v:
Journal of Clinical Oncology. 29:690-697
Purpose The proteasome inhibitor bortezomib may enhance activity of chemoimmunotherapy in lymphoma. We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients
Autor:
Frédéric Marchal, Jean-Marc Classe, Dominique Elias, Julia Bonastre, Julie Chevalier, Jean-Marc Guilloit, Diane Goéré, Antoine Brouquet, Gwenael Ferron, Jérémie H. Lefevre, Pierre Meeus
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2009, 27 (5), pp.681-685. ⟨10.1200/JCO.2008.19.7160⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2009, 27 (5), pp.681-685. ⟨10.1200/JCO.2008.19.7160⟩
Purpose To compare the long-term survival of patients with isolated and resectable peritoneal carcinomatosis (PC) in comparable groups of patients treated with systemic chemotherapy containing oxaliplatin or irinotecan or by cytoreductive surgery plu
Publikováno v:
Journal of Clinical Oncology. 26:2973-2978
Purpose To determine the maximum-tolerated dose (MTD) of concurrent paclitaxel and radiation therapy (RT) in patients with locally advanced prostate cancer. Materials and Methods Eligible patients had T2-4 tumors with Gleason scores greater than 7 an
Autor:
Manfred Welslau, Martin-L. Hansmann, Klaus-M. Josten, Heinz Dürk, Andreas Rost, Salah-Eddin Al-Batran, Soo-Z. Kim, Paris S. Mitrou, Dorothea Kofahl-Krause, Michael Neise, Kai U. Chow, Ulrich von Grünhagen, Ralf Hecker, Dieter Hoelzer, Mathias J. Rummel
Publikováno v:
Journal of Clinical Oncology. 23:3383-3389
Purpose The aim of this multicenter-study was to evaluate the progression-free survival, response rate and toxicity of the combination of bendamustine and rituximab (BR) in patients with mantle cell or low-grade lymphomas in first to third relapse or
Publikováno v:
JCO Clinical Cancer Informatics. :56-65
PURPOSE To compare and characterize overall survival (OS) differences between clinical trial data from the KEYNOTE-010 trial and real-world data (RWD) from the Flatiron Health database in patients with programmed death ligand 1 (PD-L1)–expressing a
Autor:
Brian N. Bundy, Frederick B. Stehman, Jo Ann Benda, Daniel L. Clarke-Pearson, Mahesh A. Varia, Ronald D. Alvarez, Harry J. Long
Publikováno v:
Journal of Clinical Oncology. 21:2849-2855
Purpose: The objectives of this prospective randomized study of consolidation therapy were to evaluate recurrence-free survival (RFS), overall survival (OS), and the morbidity of intraperitoneal (IP) chromic phosphate suspension (32P) therapy in pati
Autor:
David Malka, Cedric Lecaille, Anne-Laure Bignon, Nicolas Williet, Caroline Pétorin, Thomas Aparicio, Jérôme Desramé, Jean-Marc Phelip, Côme Lepage, Eric Francois, Yves Rinaldi, Anthony Turpin, Prodige Investigators, Karine Le Malicot, Laetitia Dahan, Jean-François Seitz, Christine Rebischung, Olivier Bouché, Jean-Baptiste Bachet
Publikováno v:
Journal of Clinical Oncology. 39:3242-3250
PURPOSE Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4—ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over